TSX higher on employment data
Investing.com - KeyBanc upgraded Alignment Healthcare Inc (NASDAQ:ALHC) from Sector Weight to Overweight on Monday, setting a price target of $21.00. The stock, which has delivered an impressive 71% return over the past year and is currently trading near $15.84, shows strong momentum with a 41% gain year-to-date. According to InvestingPro analysis, the company appears fairly valued at current levels.
The upgrade reflects KeyBanc’s view that Alignment Healthcare is "emerging as a better MA-VBC mousetrap vs. traditional models," with its platform consistently improving hospital utilization while reinvesting savings into member benefits.
KeyBanc believes Alignment’s integrated Medicare Advantage-value-based care model positions the company for long-term market share gains and above-average growth compared to competitors.
The research firm’s analysis suggests Alignment Healthcare is well positioned to drive significant EBITDA growth in 2026 and 2027, supported by cohort maturation, Stars funding advantages, and improved Medicare Advantage rates.
KeyBanc also noted that Alignment’s guidance assumptions for the second half of 2025 appear conservative, with positive near-term catalysts including Stars ratings and potential commentary about 2026 performance.
In other recent news, Alignment Healthcare reported its second-quarter 2025 earnings, delivering a standout performance that caught the attention of investors and analysts alike. The company achieved earnings per share (EPS) of $0.07, significantly exceeding the forecasted -$0.07. Additionally, Alignment Healthcare’s revenue reached $1 billion, surpassing the expected $960.51 million, which indicates robust business growth. Barclays (LON:BARC) responded to these results by upgrading the company’s stock rating from Underweight to Equalweight and raising the price target from $9.00 to $13.00. The upgrade was influenced by revenue that was 6% above forecasts and an EBITDA that exceeded expectations by $32 million for core operations. Furthermore, the company experienced membership growth that was 1% above projections. These developments highlight Alignment Healthcare’s strong financial performance and the positive outlook from analysts at Barclays.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.